25/05/2026
The Ebola outbreak currently unfolding in DRC and Uganda has, as you know, now been declared a public health emergency of international concern by WHO.
As there is still no approved vaccine available, Ebola research demands tools that perform across the full pipeline – from survivor cohort studies to pre-clinical vaccine models to Phase I clinical trials. Mabtech ELISpot and FluoroSpot kits have been used at every one of those stages.
Check it out:
- A 2020 Lancet Infectious Diseases study (Thom et al.) used our ELISpot to quantify glycoprotein-specific T cell responses in 116 Ebola virus disease survivors in Guinea, contributing key evidence on the durability of protective immunity after natural infection.
- A 2019 PLoS Pathogens study (Rahim et al.) used our FluoroSpot to evaluate vaccine-elicited T cell responses in a pan-filovirus challenge model, demonstrating complete protection against both Ebola and Marburg viruses in mice.
- And an NIH Vaccine Research Center Phase I trial (Sarwar et al., Journal of Infectious Diseases, 2015) used Mabtech ELISpot as the primary immunogenicity readout for Ebolavirus and Marburgvirus DNA vaccine candidates in human subjects.
Having a validated, publication-ready assay platform matters. We are proud that our tools are supporting this work.
If you are working on the immune response to Ebola or filovirus vaccine development, we would be glad to (continue to) support your work. So please get in touch if you need anything! https://hubs.li/Q04hN8LW0
